-
「同位素标记抑制剂」CAS:2050041-12-6|Ledipasvir-d6
作者：德尔塔生物 日期：2025-06-13
生物活性：Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Ledipasvir-d6 相关抗体:Cyclophilin A AntibodyCyclophilin B Antibody (YA787)分子量：895.04Formula：C49H48D6F2N8O6CAS 号：2050041-12-6非标记 CAS：1256388-51-8性状：固体颜色：Light yellow to yellow中文名称：雷迪帕韦 d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month
-
「同位素标记抑制剂」CAS:1298086-22-2|Ertugliflozin-d5
作者：德尔塔生物 日期：2025-06-13
生物活性：Ertugliflozin-d5 is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：441.91Formula：C22H20D5ClO7CAS 号：1298086-22-2非标记 CAS：1210344-57-2中文名称：埃格列净-d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (538 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. [Content Brief][3]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Dru
-
「同位素标记抑制剂」CAS:1189992-00-4|Roflumilast-d3
作者：德尔塔生物 日期：2025-06-13
生物活性：Roflumilast-d3 is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Roflumilast-d3 相关抗体:Acetyl CoA synthetase AntibodyPDE1B Antibody (YA1553)PDE4B Antibody (YA2932)PDE2A Antibody (YA2989)PDE4D Antibody (YA1714)分子量：406.23Formula：C17H11D3Cl2F2N2O3CAS 号：1189992-00-4非标记 CAS：162401-32-3中文名称：罗氟司特-d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [Content Brief][3]. Rabe KF. Update on roflumilast, a phosp
-
「同位素标记抑制剂」CAS:1398065-69-4|Roflumilast-d4
作者：德尔塔生物 日期：2025-06-13
生物活性：Roflumilast-d4 is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Roflumilast-d4 相关抗体:Acetyl CoA synthetase AntibodyPDE1B Antibody (YA1553)PDE4B Antibody (YA2932)PDE2A Antibody (YA2989)PDE4D Antibody (YA1714)分子量：407.23Formula：C17H10D4Cl2F2N2O3CAS 号：1398065-69-4非标记 CAS：162401-32-3中文名称：罗氟司特 d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [Content Brief][3]. Rabe KF. Update on roflumilas
-
「同位素标记抑制剂」CAS:2748267-73-2|Etoricoxib-13C,d3
作者：德尔塔生物 日期：2025-06-13
生物活性：Etoricoxib-13C,d3 is the 13C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[66].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Etoricoxib-13C,d3 相关抗体:COX2 AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCOX IV Antibody (YA867)Cyclooxygenase 1 Antibody (YA2537)Cyclooxygenase 2 Antibody (YA2541)分子量：362.85Formula：C1713CH12D3ClN2O2SCAS 号：2748267-73-2非标记 CAS：202409-33-4中文名称：依托考昔-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief][2]. Riendeau D, et al.Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66. [Content Brief][3]. Kunak CS, et al. The Effect of Et
-
「同位素标记抑制剂」CAS:1564241-79-7|Baricitinib-d5
作者：德尔塔生物 日期：2025-06-13
生物活性：Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Baricitinib-d5 相关抗体:Phospho-JAK2 (Tyr1007/1008) AntibodyJAK1 Antibody (YA722)JAK1 AntibodyJAK2 Antibody (YA721)Phospho-JAK2 (Tyr1007+Tyr1008) AntibodyJAK2 Antibody (YA330)Phospho-JNK (Thr183) AntibodyJAK3 Antibody (YA2466)分子量：376.45Formula：C16H12D5N7O2SCAS 号：1564241-79-7非标记 CAS：1187594-09-7中文名称：巴瑞克替尼 d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (533 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307. [Content Brief][3]. Jabbari A, et al. Reversal of Alopecia Areata
-
「同位素标记抑制剂」CAS:2738376-76-4|Cabergoline-d6
作者：德尔塔生物 日期：2025-06-13
生物活性：Cabergoline-d6 is deuterium labeled Cabergoline. Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).IC50 & Target：D3 ReceptorD2 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Cabergoline-d6 相关抗体:DRD2 AntibodyDopamine Receptor D3 Antibody (YA1742)DOPA Decarboxylase Antibody (YA2428)Dopamine Receptor D1 Antibody (YA3270)Torsin 1A Antibody (YA2935)PITX3 Antibody (YA2974)HMBS Antibody (YA3061)分子量：457.64Formula：C26H31D6N5O2CAS 号：2738376-76-4非标记 CAS：81409-90-7中文名称：卡麦角林-d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (532 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Odaka H, et al. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014 Jun 10;9(6):e99271. [Content Brief][3]. Jefferson F, et al. A
-
「同位素标记抑制剂」CAS:1189919-49-0|Prasugrel-d4
作者：德尔塔生物 日期：2025-06-13
生物活性：Prasugrel-d4 is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Prasugrel-d4 相关抗体:P2Y12 Antibody (YA3135)P2Y6 Antibody (YA1691)分子量：377.47Formula：C20H16D4FNO3SCAS 号：1189919-49-0非标记 CAS：150322-43-3中文名称：普拉格雷-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647-57. [Content Brief][3]. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's act
-
「同位素标记抑制剂」CAS:1127252-92-9|Prasugrel-d5
作者：德尔塔生物 日期：2025-06-13
生物活性：Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].IC50 & Target：P2Y12 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Prasugrel-d5 相关抗体:P2Y12 Antibody (YA3135)P2Y6 Antibody (YA1691)分子量：378.47Formula：C20H15D5FNO3SCAS 号：1127252-92-9非标记 CAS：389574-19-0中文名称：普拉格雷-d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (532 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647-57. [Content Brief][3]. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of
-
「同位素标记抑制剂」CAS:1613250-18-2|Faldaprevir-d7
作者：德尔塔生物 日期：2025-06-13
生物活性：Faldaprevir-d7 is deuterium labeled Faldaprevir.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：876.86Formula：C40H42D7BrN6O9SCAS 号：1613250-18-2非标记 CAS：801283-95-4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (528 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1261734-88-6|Pazopanib-13C,d3
作者：德尔塔生物 日期：2025-06-13
生物活性：Pazopanib-13C,d3 is the deuterium and 13C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Pazopanib-13C,d3 相关抗体:FGFR2/CD332 Antibodyc-Kit Antibody (YA502)Phospho-PDGFR beta (Y740) AntibodyVEGF Receptor 2 Antibody (YA014)FGFR1 AntibodyFGFR1 Oncogene Partner AntibodyFGFR2 AntibodyFGFR3 AntibodyPDGFR alpha AntibodyFGF2 AntibodyVEGF Receptor 1 AntibodyVEGFA AntibodyVEGF Receptor2 Antibody FGF1 Antibody (YA1430)PDGF B Antibody (YA1556)FGFR4 Antibody (YA1588)PLGF Antibody (YA1812)PDGFR beta Antibody (YA1925)VEGFD Antibody (YA2385)FGF19 Antibody (YA2672)TACC3 Antibody (YA2921)Phospho-PDGFR beta (Tyr740) Antibody (YA3062)FGF21 Antibody (YA3276)c-Kit AntibodySCF AntibodyPGF Antibody (YA1434)Neuropilin 1 Antibody (YA1831)VEGFB Antibody (YA2627)分子量：441.53Formula：C2013CH20D3N7O2SCAS 号：1261734-88-6非标记 CAS：444731-52-6中文名称：帕唑帕尼-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of
-
「同位素标记抑制剂」CAS:1207560-07-3|Sorafenib-d4
作者：德尔塔生物 日期：2025-06-13
生物活性：Sorafenib-d4 is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.分子量：468.85Formula：C21H12D4ClF3N4O3CAS 号：1207560-07-3非标记 CAS：284461-73-0中文名称：索拉非尼-d4；索拉菲尼-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [Content Brief]
-
「同位素标记抑制剂」CAS:211105-29-2|Prostaglandin D2-d4
作者：德尔塔生物 日期：2025-06-13
生物活性：Prostaglandin D2-d4 is the deuterium labeled Prostaglandin D2. Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals[1]. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances[2]. PGD2 plays a protective role by suppressing inflammation[3].IC50 & Target：DP体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Prostaglandin D2-d4 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：356.49Formula：C20H28D4O5CAS 号：211105-29-2非标记 CAS：41598-07-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommende
-
「同位素标记抑制剂」CAS:1356347-42-6|Prostaglandin E2-d9
作者：德尔塔生物 日期：2025-06-13
生物活性：Prostaglandin E2-d9 is the deuterium labeled Prostaglandin E2. Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation[1][2].IC50 & Target：EP体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Prostaglandin E2-d9 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：361.52Formula：C20H23D9O5CAS 号：1356347-42-6非标记 CAS：363-24-6中文名称：前列腺素 E2 d9运输条件：Room temperature in continental US; may vary elsewhere.储存方
-
「同位素标记抑制剂」CAS:202114-53-2|Fmoc-leucine-13C
作者：德尔塔生物 日期：2025-06-13
生物活性：Fmoc-leucine-13C is a 13C-labeled Boc-Glycine[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[75].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Fmoc-leucine-13C 相关抗体:PPAR alpha AntibodyPPAR gamma AntibodyPPAR gamma Antibody (YA122)PGC1 beta Antibody (YA1411)分子量：354.40Formula：C2013CH23NO4CAS 号：202114-53-2非标记 CAS：35661-60-0中文名称：Fmoc-L-亮氨酸-13C运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
咨询热线
18133906270
德尔塔官方微信